Search results
10 sie 2020 · The primary purpose of these guidelines is to minimize the side-effects of IV injection, by suggesting proper and prompt emergency measures for extravasation and the appropriate treatments corresponding to the properties of the injected drug.
Large, well-designed, controlled clinical trials in humans are not available to support the development of extravasation management guidelines. Available data generally consists of case reports, trials utilizing animal models, and small studies with evidence of poor or inconsistent quality.
Skin blanched, translucent DAUNorubicin* X X € Mild to moderate pain Dextrose >10%* X X € Gross edema >6" in any direction Diazepam X € Cool to touch Digoxin X X X € Possible numbness DOBUTamine X € Skin blanched, translucent Docetaxel X € Moderate to severe pain DOPamine* X € Skin tight, leaking DOXorubicin X X € Skin ...
1 sie 2009 · Abstract. Practice guidelines for therapeutic monitoring of vancomycin treatment for Staphylococcus aureus infection in adult patients were reviewed by an expert panel of the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.
10 kwi 2007 · Severe local vancomycin induced skin necrosis. Vancomycin is a glycopeptide antibiotic with activity against gram-positive bacteria, used in the treatment of endocarditis, as an alternative to penicillin in the case of allergy and is the drug of choice for the treatment of infections due to methicillin-resistant staphylococci (MRSA).
1 kwi 2019 · Vancomycin, linezolid, tigecycline, daptomycin, ceftaroline, and telavancin are all considered appropriate antimicrobial agents for treatment of severe purulent infections, while trimethoprim-sulfamethoxazole and doxycycline are recommended for moderate purulent infections.
1 sie 2009 · A literature review of existing evidence regarding vancomycin dosing and monitoring of serum concentrations, in addition to patient outcomes combined with expert opinion regarding the drug's pharmacokinetic, pharmacodynamic, and safety record, resulted in new recommendations for targeting and adjustment of vancomycin therapy.
